Clinical comparison of two topical prednisolone acetate 1% formulations in reducing inflammation after cataract surgery

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2325-2331

  Raizman, Michael B ^a   Donnenfeld, Eric D ^b   Weinstein, Arthur J ^c  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

^c Albuquerque Ambulatory Eye Surgery Center   (United States)

Author keywords

Corticosteroid bioavailability; Phacoemulsification; Postoperative inflammation; Prednisolone acetate

Indexed keywords

OMNIPRED; PREDNISOLONE ACETATE; UNCLASSIFIED DRUG;

ARTICLE; BLURRED VISION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; EYE COLOR; EYE PAIN; HUMAN; INTRAOCULAR PRESSURE; IRITIS; LENS IMPLANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHACOEMULSIFICATION; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PERIOD; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SCLERITIS; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; CATARACT EXTRACTION; CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; HUMANS; INFLAMMATION; LENS IMPLANTATION, INTRAOCULAR; PAIN, POSTOPERATIVE; PREDNISOLONE; TREATMENT OUTCOME;

EID: 35649013813     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X226195     Document Type: Article

References (12)

1. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005;21:1131-7
2. Gayton JL. A clinical comparison of two different prednisolone acetate formulations in patients undergoing cataract surgery. Curr Med Res Opin 2005;21:1291-5
3. Omnipred [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2006
4. Pred Forte [package insert]. Irvine, CA: Allergan, Inc., 2001
5. FDA Electronic Orange Book. Food and Drug Administration website. Available at: http://www.fda.gov/cder/ob/default.htm (Accessed June 1, 2007)
6. Alcon Laboratories, Personal communication, June 1, 2007
7. McGhee CNJ, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids. Benefits and risks. Drug Safety 2002;25:33-55
8. Alcon Laboratories (Alcon Lab Notebook Reference LN 13206:022)
9. Roberts CW, Nelson PL. Comparative analysis of prednisolone acetate suspensions. J Ocular Pharmacol Ther 2007;23:182-7
10. Owen GR, Brooks AC, James O, Robertson SM. A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues. J Ocular Pharmacol Ther 2007;4:335-42
11. Katz JA, Owen GR, Robertson SM, et al. A new in vivo rabbit model that mimics human dosing to determine the distribution of 1.0% prednisolone acetate suspensions in the tears and aqueous humor. Invest Ophthalmol Vis Sci 2007;48:4314
12. McGhee CNJ, Watson DG, Midgley JM, et al. Penetration of synthetic corticosteroids into human aqueous humour. Eye 1990;4:526-30